Delivery Order SPE2DB20D3103-SPE2DB25FP4Z9
- Not listed
- The Defense Logistics Agency awarded a $2,724.55 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government...
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a $43,449.54 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors on September 24, 2025, with a completion date of September 25, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a single-transaction purchase under the company's broader relationship with the...
- The Defense Logistics Agency awarded a $14,615.04 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 18, 2025, with completion scheduled for July 21, 2025. This contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $4,839.72 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is expected to be completed by September 15, 2025, and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $14,343.19 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $10,285.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of August 15, 2025, and performance to be executed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract issued under AmerisourceBergen's broader relationship with the Defense...
- The Defense Logistics Agency awarded a $4,868.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors on September 11, 2025, with completion expected by September 12, 2025. This non-set-aside contract represents a single delivery order fulfillment for the diabetes and weight management medication, performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award reflects the company's role as a...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP4Z9Delivery Order
The Defense Logistics Agency awarded a $22,877.40 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors on July 14, 2025, with completion targeted for July 15, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical commodities to support military healthcare systems worldwide. AmerisourceBergen's federal contract history demonstrates consistent capability in fulfilling competitive pharmaceutical procurement requirements for the Defense Health Agency and other government healthcare systems through open competition, positioning the company as a critical vendor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.9k | 7/14/25 |